{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:14:38Z","timestamp":1762506878366},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00774-016-0771-x","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T08:42:39Z","timestamp":1472200959000},"page":"419-427","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5\u00a0mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice"],"prefix":"10.1007","volume":"35","author":[{"given":"Satoshi","family":"Soen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Kamisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"771_CR1","unstructured":"Guidelines for prevention and treatment of osteoporosis (2011) Life Science Publishing Co., Ltd, Japan"},{"key":"771_CR2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00776-005-0998-1","volume":"11","author":"K Sakamoto","year":"2006","unstructured":"Sakamoto K, Nakamura T, Hagino H, Endo N, Mori S, Muto Y, Harada A, Nakano T, Yamamoto S, Kushida K, Tomita K, Yoshimura M, Yamamoto H (2006) Report on the Japanese Orthopaedic Association\u2019s 3-year project observing hip fractures at fixed-point hospitals. J Orthop Sci 11:127\u2013134","journal-title":"J Orthop Sci"},{"key":"771_CR3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Col\u00f3n-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380\u2013390","journal-title":"Ann Intern Med"},{"key":"771_CR4","first-page":"745","volume":"18","author":"H Ohta","year":"2010","unstructured":"Ohta H, Itabashi A, Umemura T, Kamisaki K, Nishikawa M, Shirai K (2010) Safety and effectiveness profile of risedronate 2.5\u00a0mg tablet in 12 months prospective observational study including male osteoporosis. Osteoporos Jpn 18:745\u2013753","journal-title":"Osteoporos Jpn"},{"key":"771_CR5","first-page":"551","volume":"20","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Umemura T, Kamisaki T, Nishikawa M, Uchida S (2012) QOL-change and examination of factors by treatment of risedronate 2.5\u00a0mg for patients with osteoporosis. Osteoporos Jpn 20:551\u2013563","journal-title":"Osteoporos Jpn"},{"key":"771_CR6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00774-012-0406-9","volume":"31","author":"S Itoh","year":"2013","unstructured":"Itoh S, Sekino Y, Shinomiya K, Takeda S (2013) The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab 31:206\u2013211","journal-title":"J Bone Miner Metab"},{"key":"771_CR7","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) study group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"771_CR8","doi-asserted-by":"crossref","unstructured":"Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G; Osteoporosis Methodology Group; The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517\u2013523","DOI":"10.1210\/er.2001-3002"},{"key":"771_CR9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"771_CR10","first-page":"469","volume":"22","author":"K Kushida","year":"2004","unstructured":"Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedoronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22:469\u2013478","journal-title":"J Bone Miner Metab"},{"key":"771_CR11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00774-013-0490-5","volume":"32","author":"Y Kasukawa","year":"2014","unstructured":"Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chiba S, Shimada Y (2014) Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab 32:290\u2013297","journal-title":"J Bone Miner Metab"},{"key":"771_CR12","doi-asserted-by":"crossref","unstructured":"Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y; Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5\u00a0mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405\u2013413","DOI":"10.1007\/s00774-006-0706-z"},{"key":"771_CR13","first-page":"697","volume":"20","author":"H Ohta","year":"2012","unstructured":"Ohta H, Nishikawa M, Kamisaki T, Umemura T, Itoh M, Uchida S (2012) Safety and efficacy of risedronate 17.5\u00a0mg tablets in prospective observation study including male patients with osteoporosis-48 weeks treatment by risedronate 17.5\u00a0mg tablets under good post-marketing study practice. Osteoporos Jpn 20:697\u2013707","journal-title":"Osteoporos Jpn"},{"key":"771_CR14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00774-012-0372-2","volume":"30","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Osawa M, Itoh M, Yamaguchi H, Iinuma N, Hayakawa Y, Suzuki H, Kamisaki T, Iwayama S, Nishikawa M (2012) The effect of risedronate (17.5\u00a0mg\/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. J Bone Miner Metab 30:715\u2013721","journal-title":"J Bone Miner Metab"},{"key":"771_CR15","doi-asserted-by":"crossref","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H; Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337","DOI":"10.1007\/s007740170001"},{"key":"771_CR16","first-page":"533","volume":"5","author":"M Shiraki","year":"1997","unstructured":"Shiraki M, Shiraki Y, Sasaki K, Aoki N (1997) Clinical research of prevention of osteoporosis fracture. Osteoporos Jpn 5:533\u2013539","journal-title":"Osteoporos Jpn"},{"key":"771_CR17","doi-asserted-by":"crossref","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429\u20131437","DOI":"10.1007\/s00198-008-0816-7"},{"key":"771_CR18","doi-asserted-by":"crossref","unstructured":"Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H; MOVER Study Group (2013) Clinical efficacy on fracture risk and safety of 0.5\u00a0mg or 1\u00a0mg\/month intravenous ibandronate versus 2.5\u00a0mg\/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137\u2013146","DOI":"10.1007\/s00223-013-9734-6"},{"key":"771_CR19","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00198-010-1498-5","volume":"22","author":"A Fahrleitner-Pammer","year":"2011","unstructured":"Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, Ljunggren \u00d6, Walsh JB, Rajzbaum G, Barker C, Lems WF (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22:2709\u20132719","journal-title":"Osteoporos Int"},{"key":"771_CR20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis for whom and for how long? N Engl J Med 366:2051\u20132053","journal-title":"N Engl J Med"},{"key":"771_CR21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00774-013-0546-6","volume":"32","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto T, Taketsuna M, Guo X, Sato M, Sowa H (2014) The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report. J Bone Miner Metab 32:699\u2013708","journal-title":"J Bone Miner Metab"},{"key":"771_CR22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00198-011-1556-7","volume":"23","author":"M Osaki","year":"2012","unstructured":"Osaki M, Tatsuki K, Hashikawa T, Norimatsu T, Chiba K, Motokawa S, Furuichi I, Doiguchi Y, Aoyagi K, Shindo H (2012) Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 23:695\u2013703","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-016-0771-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-016-0771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-016-0771-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-016-0771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T17:06:28Z","timestamp":1498755988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-016-0771-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s00774-016-0771-x","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]}}}